Immunomodulatory treatments for aspirin exacerbated respiratory disease

American Journal of Rhinology and Allergy

Volumn 26, Issue 2, 2012, Pages 134-140

  Moebus, Rachel G ^a   Han, Joseph K ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANTIHISTAMINIC AGENT; CORTICOSTEROID; KETOROLAC TROMETAMOL; MONTELUKAST; PEPTIDOLEUKOTRIENE; PREDNISONE; ZAFIRLUKAST; ZILEUTON;

ADRENAL GLAND; ANGIONEUROTIC EDEMA; ASPIRIN EXACERBATED RESPIRATORY DISEASE; CORTICOSTEROID THERAPY; DESENSITIZATION; DRUG DOSE INCREASE; DRUG SENSITIVITY; ENDOSCOPIC SINUS SURGERY; EPIGASTRIC PAIN; EPISTAXIS; EYE DISEASE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOMODULATION; LARYNX EDEMA; LARYNX SPASM; LIVER TOXICITY; MEDICAL HISTORY; NOSE DISEASE; OBESITY; OSTEOPOROSIS; POLYPECTOMY; PREVALENCE; RESPIRATORY TRACT DISEASE; REVIEW; RHINOSINUSITIS; SIDE EFFECT; STEROID THERAPY; STOMACH IRRITATION; TREATMENT FAILURE; TREATMENT RESPONSE; URTICARIA;

ADRENAL CORTEX HORMONES; ASPIRIN; ASTHMA, ASPIRIN-INDUCED; DESENSITIZATION, IMMUNOLOGIC; ENDOSCOPY; ENZYME INHIBITORS; HUMANS; IMMUNOMODULATION; LEUKOTRIENES; LIPOXYGENASE; NASAL POLYPS; RHINITIS; SINUSITIS;

EID: 84860183341     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2012.26.3748     Document Type: Review

References (58)

1. Gilbert G. Unusual idiosyncrasy to aspirin. JAMA 56:1262, 1911.
2. Widal MF, Abrami P, and Lenmoyez J. Anaphylaxie et idiosyncrasie. Presse Med 30:189-193, 1922.
3. Samter M, and Beers R Jr. Intolerance to aspirin: Clinical studies and consideration of its pathogenesis. Ann Intern Med 68:975-983, 1968.
4. Szczeklik A, and Nizankowska E. Clinical features and diagnosis of aspirin induced asthma. Thorax 55(suppl 2):S42-S44, 2000. (Available online at www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1765966&tool= pmcentrez&rendertype=abstract; accessed June 14, 2011.)
5. Szczeklik A, Nizankowska E, and Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 16:432-436, 2000. (Available online at www.ncbi.nlm.nih.gov/pubmed/11028656; accessed June 14, 2011.)
6. Berges-Gimeno MP, Simon RA, and Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 89:474-478, 2002. Available online at www.ncbi.nlm.nih.gov/ pubmed/12452205; accessed June 14, 2011.
7. Marquette CH, Saulnier F, Leroy O, et al. Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis 146:76-81, 1992. (Available online at www.ncbi.nlm.nih.gov/pubmed/ 1626819; accessed June 14, 2011.)
8. Katotomichelakis M, Riga M, Davris S, et al. Allergic rhinitis and aspirin-exacerbated respiratory disease as predictors of the olfactory outcome after endoscopic sinus surgery. Am J Rhinol Allergy 23:348-353, 2009. (Available online at www.ncbi.nlm.nih.gov/pubmed/19490814; accessed September 17, 2011.)
9. Pfaar O, and Klimek L. Aspirin desensitization in aspirin intolerance: Update on current standards and recent improvements. Curr Opin Allergy Clin Immunol 6:161-166, 2006. (Available online at www.ncbi.nlm.nih.gov/pubmed/ 16670507; accessed June 14, 2011.)
10. Gamboa P, Sanz ML, Caballero MR, et al. The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin Exp Allergy 34:1448-1457, 2004. (Available online at www.ncbi.nlm.nih.gov/pubmed/15347380; accessed July 14, 2011.
11. Stevenson DD, and Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 118:773-786, 2006. (Available online at www.ncbi.nlm.nih.gov/pubmed/17030227; accessed April 5, 2011.)
12. White A, Bigby T, and Stevenson D. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 97:190-195, 2006. (Available online at www.ncbi.nlm.nih.gov/pubmed/ 16937750; accessed July 14, 2011.)
13. Szczeklik A, Sanak M, Nizankowska-Mogilnicka E, and Kiełbasa B. Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Curr Opin Pulm Med 10:51-56, 2004. (Available online at www.ncbi.nlm.nih.gov/pubmed/14749606; accessed June 14, 2011.)
14. Hedman J, Kaprio J, Poussa T, and Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 28:717-722, 1999. (Available online at www.ncbi.nlm.nih.gov/pubmed/10480701; accessed April 6, 2011.)
15. Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 347:1493-1499, 2002. (Available online at www.ncbi.nlm.nih.gov/pubmed/ 12421891; accessed May 9, 2011.)
16. Macy E, Bernstein JA, Castells MC, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: A practice paper. Ann Allergy Asthma Immunol 98:172-174, 2007. Available online at www.ncbi.nlm.nih.gov/pubmed/17304886; accessed July 6, 2011.)
17. Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 153:572-575, 1996. (Available online at www.ncbi.nlm.nih.gov/pubmed/8564100; accessed July 15, 2011.)
18. Schüfer D, Schmid M, Göde UC, and Baenkler HW. Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur Respir J 13:638-646, 1999. (Available online at www.ncbi.nlm.nih.gov/pubmed/10232440; accessed July 15, 2011.)
19. Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirinintolerant asthma. J Clin Investig 101:834-846, 1998. (Available online at www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=508632&tool=pmcentrez&rendertype=abstract; accessed July 14, 2011.)
20. Higashi N, Taniguchi M, Mita H, et al. Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 113:277-283, 2004. (Available online at www.ncbi.nlm.nih.gov/pubmed/14767442; accessed June 12, 2011.)
21. Kim S-H, Yang E-M, Lee H-N, et al. Combined effect of IL-10 and TGF-beta1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis. Allergy 64:1221-1225, 2009. (Available online at www.ncbi.nlm.nih.gov/pubmed/19222424; accessed June 15, 2011.)
22. Sanak M, Levy BD, Clish CB, et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 16:44-49, 2000. (Available online at www.ncbi.nlm.nih.gov/pubmed/10933083; accessed July 22, 2011.)
23. Umemoto J, Tsurikisawa N, Nogi S, et al. Selective cyclooxygenase-2 inhibitor cross-reactivity in aspirin-exacerbated respiratory disease. Allergy Asthma Proc 32:259-261, 2011. (Available online at www.ncbi.nlm.nih.gov/pubmed/ 21703104; accessed September 19, 2011.)
24. Baldassarre S, Schandene L, Choufani G, and Michils A. Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen. J Allergy Clinl Immunol 117:215-217, 2006. (Available online at www.ncbi.nlm.nih.gov/pubmed/ 16387610; accessed September 19, 2011.)
25. Lee RU, and Stevenson DD. Aspirin-exacerbated respiratory disease: Evaluation and management. Allergy Asthma Immunol Res 3:3-10, 2011. (Available online at www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3005316&tool= pmcentrez&rendertype=abstract accessed July 15, 2011.)
26. Capra V. Molecular and functional aspects of human cysteinyl leukotriene receptors. Pharmacol Res 50:1-11, 2004. (Available online at www.ncbi.nlm.nih.gov/pubmed/15082024; accessed July 21, 2011.)
27. DeMarcantonio MA, and Han JK. Systemic therapies in managing sinonasal inflammation. Otolaryngol Clin North Am 43:551-563, 2010. (Available online at www.ncbi.nlm.nih.gov/pubmed/20525510; accessed June 15, 2011.)
28. Schäper C, Noga O, Koch B, et al. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol 21:51-58, 2011. (Available online at www.ncbi.nlm.nih.gov/pubmed/21370724; accessed July 21, 2011.)
29. Tintinger GR, Feldman C, Theron AJ, and Anderson R. Montelukast: More than a cysteinyl leukotriene receptor antagonist? Sci World J 10:2403-2413, 2010. (Available online at www.ncbi.nlm.nih.gov/pubmed/21170491; accessed July 21, 2011.)
30. Dahlén B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 157:1187-1194, 1998. (Available online at www.ncbi.nlm.nih.gov/pubmed/9563738; accessed June 11, 2011.)
31. Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 94:1046-1056, 1994. (Available online at www.ncbi.nlm.nih.gov/pubmed/7798537; accessed April 11, 2011.)
32. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 148:1447-1451, 1993. (Available online at www.ncbi.nlm.nih.gov/pubmed/8256883; accessed June 15, 2011.)
33. Rossi A, Pergola C, Koeberle A, et al. The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages. Br J Pharmacol 161:555-570, 2010. (Available online at www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2990155&tool= pmcentrez&rendertype=abstract; accessed July 15, 2011.)
34. Watkins PB, Dube LM, Walton-Bowen K, et al. Clinical pattern of zileuton-associated liver injury: Results of a 12-month study in patients with chronic asthma. Drug Saf 30:805-815 2007. (Available online at www.ncbi.nlm.nih.gov/pubmed/17722971; accessed July 14, 2011.)
35. Wenzel S, Busse W, Calhoun W, et al. The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: A 6-month randomized controlled study. J Asthma 44:305-310, 2007. (Available online at www.ncbi.nlm.nih.gov/pubmed/17530530; accessed July 16, 2011.)
36. Mastalerz L, Milewski M, Duplaga M, et al. Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma. Allergy 52:895-900, 1997. (Available online at www.ncbi.nlm.nih.gov/ pubmed/9298173; accessed July 14, 2011.)
37. Steinke JW, Payne SC, Tessier ME, et al. Pilot study of budesonide inhalant suspension irrigations for chronic eosinophilic sinusitis. J Allergy Clin Immunol 124:1352-1354.e7, 2009. (Available online at www.ncbi.nlm.nih.gov/ pubmed/19910027; accessed July 15, 2011.)
38. Jankowski R, and Bodino C. Evolution of symptoms associated to nasal polyposis following oral steroid treatment and nasalization of the ethmoid-radical ethmoidectomy is functional surgery for NPS. Rhinology 41:211-219, 2003. (Available online at www.ncbi.nlm.nih. gov/pubmed/14750348; accessed July 15, 2011.)
39. Nizankowska E, Bestyńska-Krypel A, Cmiel A, and Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 15:863-869, 2000. (Available online at www.ncbi.nlm.nih. gov/pubmed/10853850; accessed July 14, 2011.)
40. Hissaria P, Smith W, Wormald PJ, et al. Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures. J Allergy Clin Immunol 118:128-133, 2006. (Available online at www.ncbi.nlm.nih.gov/pubmed/ 16815148; accessed July 25, 2011.)
41. Szczeklik A. Hypersensitivity to systemic corticosteroids in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 128:904-905, 2011. (Available online at www.ncbi.nlm.nih.gov/pubmed/21700324; accessed July 22, 2011.)
42. Zeiss CR, and Lockey RF. Refractory period to aspirin in a patient with aspirin-induced asthma. J Allergy Clin Immunol 57:440-448, 1976. (Available online at www.ncbi.nlm.nih.gov/pubmed/770552; accessed June 15, 2011.)
43. Berges-Gimeno MP, Simon RA, and Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 111:180-186, 2003. (Available online at www.ncbi.nlm.nih.gov/pubmed/12532116; accessed June 15, 2011.)
44. Stevenson DD, Hankammer MA, Mathison DA, et al. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: Long-term outcomes. J Allergy Clin Immunol 98:751-758, 1996. (Available online at www.ncbi.nlm.nih.gov/pubmed/8876550; accessed June 15, 2011.)
45. Patriarca G, Schiavino D, Nucera E, et al. Prevention of relapse in nasal polyposis. Lancet 337:1488, 1991. (Available online at www.ncbi.nlm.nih.gov/ pubmed/1675359; accessed June 15, 2011.)
46. Stevenson DD, Simon RA, and Mathison DA. Aspirin-sensitive asthma: Tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol 66:82-88, 1980. (Available online at www.ncbi.nlm.nih.gov/pubmed/ 7381126; accessed June 15, 2011.)
47. Stevenson DD, Pleskow WW, Simon RA, et al. Aspirin-sensitive rhinosinusitis asthma: A double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 73:500-507, 1984. (Available online at www.ncbi.nlm.nih.gov/pubmed/6368649; accessed June 15, 2011.)
48. Pfaar O, and Klimek L. Eicosanoids, aspirin-intolerance and the upper airways - Current standards and recent improvements of the desensitization therapy. J Physiol Pharmacol 57(suppl 1):5-13, 2006. (Available online at www.ncbi.nlm.nih.gov/pubmed/17244950; accessed July 14, 2011.)
49. White AA, Hope AP, and Stevenson DD. Failure to maintain an aspirin-desensitized state in a patient with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 97:446-448, 2006. (Available online at www.ncbi.nlm.nih.gov/pubmed/17069096; accessed July 14, 2011.)
50. Juergens UR, Christiansen SC, Stevenson DD, and Zuraw BL. Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol 96:148-156, 1995. (Available online at www.ncbi.nlm.nih.gov/pubmed/ 7636051; accessed June 15, 2011.)
51. Katial RK, Strand M, Prasertsuntarasai T, et al. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol 126:738-744, 2010. (Available online at www.ncbi.nlm.nih.gov/pubmed/20728206; accessed June 15, 2011.)
52. Rizk H. Role of aspirin desensitization in the management of chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 19:210-217, 2011. (Available online at www.ncbi.nlm.nih.gov/pubmed/21372715; accessed July 14, 2011.)
53. White AA, and Stevenson DD. Does suppression of IL-4 synthesis by aspirin explain the therapeutic benefit of aspirin desensitization treatment? J Allergy Clin Immunol 126:745-746, 2010. (Available online at www.ncbi.nlm.nih.gov/ pubmed/20920763; accessed June 15, 2011.)
54. Rozsasi A, Polzehl D, Deutschle T, et al. Long-term treatment with aspirin desensitization: A prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 63:1228-1234, 2008. (Available online at www.ncbi.nlm.nih.gov/pubmed/18699939; accessed September 19, 2011.)
55. Sweet JM, Stevenson DD, Simon RA, and Mathison DA. Long-term effects of aspirin desensitization - Treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol 85:59-65, 1990. (Available online at www.ncbi.nlm.nih.gov/pubmed/2299107; accessed June 15, 2011.)
56. Rothe T, Achermann R, Hug J, and Karrer W. Incomplete aspirin desensitization in an aspirin-sensitive asthmatic. Int Arch Allergy Immunol 109:298-300, 1996. (Available online at www.ncbi.nlm.nih.gov/pubmed/8620101; accessed July 14, 2011.)
57. Dankner RE, and Wedner HJ. Aspirin desensitization in aspirin-sensitive asthma: Failure to maintain a desensitized state during prolonged therapy. American Rev Respiratory Dis 128:953-955, 1983. (Available online at www.ncbi.nlm.nih.gov/pubmed/6638687; accessed July 14, 2011.)
58. Lee RU, White AA, Ding D, et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 105:130-135, 2010. (Available online at www.ncbi.nlm.nih.gov/pubmed/20674823; accessed July 14, 2011.)